AQR Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.16M | Buy |
28,783
+10,021
| +53% | +$791K | ﹤0.01% | 2298 |
|
|
2025
Q4 | $1.48M | Buy |
18,762
+11,947
| +175% | +$900K | ﹤0.01% | 2328 |
|
|
2025
Q3 | $439K | Buy |
+6,815
| New | +$333K | ﹤0.01% | 2879 |
|
|
2024
Q1 | – | Sell |
-4,300
| Closed | -$214K | – | 2452 |
|
|
2023
Q4 | $214K | Buy |
+4,300
| New | +$206K | ﹤0.01% | 2190 |
|
|
2023
Q1 | – | Sell |
-7,569
| Closed | -$282K | – | 2212 |
|
|
2022
Q4 | $282K | Sell |
7,569
-141
| -2% | -$5.93K | ﹤0.01% | 1991 |
|
|
2022
Q3 | $341K | Buy |
+7,710
| New | +$325K | ﹤0.01% | 1907 |
|
|
2021
Q3 | – | Sell |
-13,434
| Closed | -$528K | – | 2281 |
|
|
2021
Q2 | $528K | Buy |
+13,434
| New | +$526K | ﹤0.01% | 1881 |
|
|
2020
Q3 | – | Sell |
-4,391
| Closed | -$259K | – | 2223 |
|
|
2020
Q2 | $259K | Sell |
4,391
-1,514
| -26% | -$84.2K | ﹤0.01% | 1933 |
|
|
2020
Q1 | $279K | Sell |
5,905
-8,236
| -58% | -$459K | ﹤0.01% | 1786 |
|
|
2019
Q4 | $852K | Sell |
14,141
-10,652
| -43% | -$635K | ﹤0.01% | 1565 |
|
|
2019
Q3 | $1.49M | Sell |
24,793
-479,149
| -95% | -$31.2M | ﹤0.01% | 1391 |
|
|
2019
Q2 | $32.4M | Buy |
503,942
+92,068
| +22% | +$6.51M | 0.04% | 473 |
|
|
2019
Q1 | $33M | Buy |
411,874
+402,227
| +4,169% | +$25.9M | 0.04% | 495 |
|
|
2018
Q4 | $522K | Sell |
9,647
-2,959
| -23% | -$151K | ﹤0.01% | 1760 |
|
|
2018
Q3 | $650K | Sell |
12,606
-4,835
| -28% | -$227K | ﹤0.01% | 1864 |
|
|
2018
Q2 | $727K | Buy |
17,441
+27
| +0.2% | +$1.2K | ﹤0.01% | 1845 |
|
|
2018
Q1 | $768K | Sell |
17,414
-813
| -4% | -$41.3K | ﹤0.01% | 1762 |
|
|
2017
Q4 | $917K | Buy |
18,227
+370
| +2% | +$20.3K | ﹤0.01% | 1713 |
|
|
2017
Q3 | $905K | Buy |
+17,857
| New | +$935K | ﹤0.01% | 1708 |
|
|
2016
Q4 | – | Sell |
-407,582
| Closed | -$14.9M | – | 2258 |
|
|
2016
Q3 | $14.9M | Sell |
407,582
-1,450,657
| -78% | -$45.4M | 0.02% | 645 |
|
|
2016
Q2 | $43.3M | Buy |
1,858,239
+1,465,004
| +373% | +$47.3M | 0.08% | 356 |
|
|
2016
Q1 | $15.9M | Sell |
393,235
-220,851
| -36% | -$8.97M | 0.03% | 593 |
|
|
2015
Q4 | $38M | Buy |
614,086
+50,333
| +9% | +$2.72M | 0.07% | 371 |
|
|
2015
Q3 | $22.8M | Buy |
563,753
+433,502
| +333% | +$22.4M | 0.05% | 450 |
|
|
2015
Q2 | $7.5M | Buy |
130,251
+4,904
| +4% | +$312K | 0.01% | 691 |
|
|
2015
Q1 | $7.98M | Buy |
125,347
+12,500
| +11% | +$848K | 0.02% | 619 |
|
|
2014
Q4 | $6.97M | Buy |
112,847
+68,600
| +155% | +$3.39M | 0.01% | 800 |
|
|
2014
Q3 | $1.72M | Sell |
44,247
-101,600
| -70% | -$3.6M | ﹤0.01% | 1345 |
|
|
2014
Q2 | $5.02M | Buy |
145,847
+90,028
| +161% | +$2.83M | 0.01% | 898 |
|
|
2014
Q1 | $2.41M | Sell |
55,819
-7,000
| -11% | -$339K | 0.01% | 1189 |
|
|
2013
Q4 | $2.5M | Buy |
62,819
+2,747
| +5% | +$97.9K | 0.01% | 1223 |
|
|
2013
Q3 | $2.25M | Buy |
60,072
+14,400
| +32% | +$430K | 0.01% | 1214 |
|
|
2013
Q2 | $1.23M | Buy |
+45,672
| New | +$971K | ﹤0.01% | 1467 |
|
Other funds holding IONS
VPM
VCM
AQR Capital Management's IONS Position: Q1 2026 in Review
AQR Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 53% in Q1 2026, buying an estimated $791K and bringing the position to 28,783 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2298.
AQR Capital Management first reported a position in IONS in Q2 2013 and has held it in 33 quarters since. The position peaked at $43.3M in Q2 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- AQR Capital Management held 28,783 shares of Ionis Pharmaceuticals worth $2.16M as of Q1 2026.
- AQR Capital Management bought 10,021 Ionis Pharmaceuticals shares in Q1 2026, an estimated $791K.
- Ionis Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2298 holding.
- AQR Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
- AQR Capital Management's Ionis Pharmaceuticals position peaked at $43.3M in Q2 2016.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.